OREANDA-NEWS. Sanofi Chief Executive Officer Olivier Brandicourt, MD, announced today a number of changes to the company’s Executive Committee, supporting Sanofi’s recently announced 2020 Strategic Roadmap.

As of June 1, 2016, the company’s Executive Committee, chaired by Olivier Brandicourt, will be comprised of the following members:

  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines and Emerging Markets*
  • J?r?me Contamine, Executive Vice President, Finance
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular*

  • Carsten Hellmann, Executive Vice President and General Manager of Merial (until Dec. 31, 2016–see below)

  • Karen Linehan, Executive Vice President, Legal Affairs and General Counsel

  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur+
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs
  • Muzammil Mansuri, Ph.D., Executive Vice President, Strategy & Business Development
  • David Meeker, MD, Executive Vice President and General Manager of Sanofi Genzyme
  • Ameet Nathwani, MD, Executive Vice President, Medical Affairs
  • Roberto Pucci, Executive Vice President, Human Resources
  • Elias Zerhouni, MD, President, Global Research & Development

*Denotes change in position for existing Executive Committee member.
+New to Executive Committee. 

The company has also announced that Pascale Witz, Executive Vice President, Diabetes & Cardiovascular, will leave the company on June 1. Since joining Sanofi in July 2013, Pascale has been a champion for driving a patient-focused, integrated-care approach to how Sanofi operates. She was instrumental in signing important strategic collaborations, including those with Verily Life Sciences (a subsidiary of Google) and Hanmi Pharmaceuticals.

Carsten Hellmann, Executive Vice President, Merial, has accepted a position as President and CEO of ALK but will stay with Sanofi until the end of the year to support the strategic business swap project with Boehringer Ingelheim.
In addition, Sanofi plans to name at a later date an Executive Vice President, Consumer Healthcare (CHC) who will be a member of the Executive Committee. This person will lead a newly created CHC global business unit, which will be formed following the anticipated completion of the business swap announced in December 2015 that consists of Sanofi’s animal health business Merial and Boehringer Ingelheim’s consumer healthcare (CHC) business. The transaction would allow Sanofi to become a global leader in CHC.

Finally, Suresh Kumar, Executive Vice President, External Affairs, has decided to return to the United States for personal reasons. Given the challenging U.S. operating environment and impending change in government leadership, Suresh has agreed to continue to represent Sanofi’s interest in the U.S. until the year-end. Olivier Brandicourt will serve as acting head of External Affairs until a replacement is found to succeed Suresh.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).